摘要
【目的】探讨霉酚酸酯在预防肾移植术后急性排斥中的作用。【方法】选择本院 10 6例肾移植受者为研究对象。随机分为霉酚酸酯治疗组 (n =5 6例 ) ,硫唑嘌呤治疗组 (n =5 0例 )进行对比研究。研究时间为术后 6个月内。【结果】霉酚酸酯治疗组急性排斥发生率 2 0 % ,较硫唑嘌呤组急性排斥反应发生率 44 %低 (P <0 0 1) ,霉酚酸酯组单用甲基强的松龙冲击缓解率 82 % ,硫唑嘌呤组 5 5 % (P <0 0 5 ) ;肝损害霉酚酸酯组发生率 10 % ,硫唑嘌呤组 2 0 % (P <0 0 1) ;巨细胞病毒等感染霉酚酸酯组发生率较少 ,而人、肾存活率高。【结论】霉酚酸酯作为一种新的抗排斥治疗药物 ,能更有效地预防肾移植术后急性排斥 。
To investigate the role of mycophenolate mofetil (MMF) in the prevention of acute rejection in renal transplantation. A total of 106 patients were randomized into two groups. One group received MMF (n=56), the other received azathioprine (Aza) (n=50). The time of the following study was within the first 6 months after transplantation. The rate of acute rejection of group receiving MMF was 20%, it′s lower than that of the group receiving Aza 44% (P<0 01). The recovery rate of acute rejection treated by methylprednisolone (MP), in MMF group 82% was higher than Aza group 55%. (P<0 05). Meanwhile the hepatotoxicity as well as cytomegalovirus (CMV) infection were lower in MMF group than those in Aza group. [Conclusion] MMF as a new anti rejection drug could more effectively prevent acute rejection than Aza after renal transplantation, and has lower toxicity and side effect.
出处
《中山医科大学学报》
CSCD
北大核心
2001年第3期215-217,共3页
Academic Journal of Sun Yat-sen University of Medical Sciences
基金
中山医科大学科研基金资助项目 ( 0 72 0 0 5 )
关键词
肾移植
急性排斥反应
预防
霉酚酸酯
renal transplantation
immunosupressant
mycophenolate mofetil
